A378800 Stock Overview
A clinical stage biotech company, develops novel inflammasome inhibitors targeting immune-mediated inflammatory disorders with high unmet medical needs and nanobody therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Shaperon Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,245.00 |
| 52 Week High | ₩6,420.00 |
| 52 Week Low | ₩1,389.00 |
| Beta | 0 |
| 11 Month Change | -11.79% |
| 3 Month Change | 5.15% |
| 1 Year Change | -51.25% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -73.99% |
Recent News & Updates
We're Keeping An Eye On Shaperon's (KOSDAQ:378800) Cash Burn Rate
Sep 02
Is Shaperon (KOSDAQ:378800) In A Good Position To Invest In Growth?
Apr 12Shareholder Returns
| A378800 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 28.7% | 0.8% | -1.0% |
| 1Y | -51.2% | 39.0% | 1.0% |
Return vs Industry: A378800 underperformed the KR Biotechs industry which returned 39% over the past year.
Return vs Market: A378800 underperformed the KR Market which returned 1% over the past year.
Price Volatility
| A378800 volatility | |
|---|---|
| A378800 Average Weekly Movement | 19.2% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A378800's share price has been volatile over the past 3 months.
Volatility Over Time: A378800's weekly volatility has increased from 13% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Seung-Yong Seong | www.shaperon.com |
Shaperon Inc., a clinical stage biotech company, develops novel inflammasome inhibitors targeting immune-mediated inflammatory disorders with high unmet medical needs and nanobody therapeutics. It offers NuGel, a gel type atopic dermatitis drug candidate in Phase 2 clinical trials; and NuSepin, an IV injection form of HY209 in Phase 2 clinical trials for use in the treatment of systemic inflammatory response syndrome. The company also provides Oral HY209, an oral formulation of HY209 for use in the treatment of neuroinflammatory diseases; and HY209 Analogues for treating chronic inflammation.
Shaperon Inc. Fundamentals Summary
| A378800 fundamental statistics | |
|---|---|
| Market cap | ₩67.67b |
| Earnings (TTM) | -₩15.35b |
| Revenue (TTM) | ₩91.24m |
741.7x
P/S Ratio-4.4x
P/E RatioIs A378800 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A378800 income statement (TTM) | |
|---|---|
| Revenue | ₩91.24m |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩91.24m |
| Other Expenses | ₩15.44b |
| Earnings | -₩15.35b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -509.08 |
| Gross Margin | 100.00% |
| Net Profit Margin | -16,819.16% |
| Debt/Equity Ratio | 0% |
How did A378800 perform over the long term?
See historical performance and comparison